Browsing Tag
Scott Plesha
2 posts
Pelthos Therapeutics to acquire Castle Creek Biosciences in gene therapy merger backed by $57.5m financing
Pelthos Therapeutics has agreed to combine with Castle Creek Biosciences, adding a late-stage gene-modified cell therapy programme to its commercial dermatology portfolio. The proposed transaction includes an initial 5.2 million-share issuance, potentially substantial additional consideration and financing arrangements that could materially reshape shareholder ownership.
What John M. Gay’s CFO appointment means for Pelthos Therapeutics (NYSE American: PTHS) and its next growth phase
Pelthos Therapeutics has named John M. Gay as CFO. Read what the move signals for Zelsuvmi growth, funding strategy, and Pelthos stock now.